Lyra Therapeutics Inc (NASDAQ:LYRA) traded at $0.36 at close of the session on Tuesday, May 21, made a downward move of -4.72% on its previous day’s price.
Looking at the stock we see that its previous close was $0.37 . In terms of its 52-week price range, LYRA has a high of $6.79 and a low of $0.35. The company’s stock has lost about -93.18% over that past 30 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lyra Therapeutics Inc has a market cap of $21.67 million. Estimates by analysts give the company expected earnings per share (EPS) of -$0.32, with the EPS growth for the year raised at -$1.21 for 2024 and -$0.93 for next year. These figures represent 4.00% and 23.10% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $360k, with a high of $530k. The median projection represents growth adding up to -21.40% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2024 is expected to hit $1.57 million, or 0.80% up from figures reported last year.
On the other hand, looking at the outlook for the LYRA stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 50% Sell.
Looking further, we note the current price level is -85.32% off its SMA20 and -91.90% from its 50-day simple moving average. The RSI (14) is pointing at 13.21 while the volatility over the past week is 11.19% and jumps to 13.50% over the past one month. The beta value is -0.02, while the average true range (ATR) is currently pointing at 0.32.
Coming back to Lyra Therapeutics Inc (NASDAQ:LYRA), we note that the average 3-month trading volume was 2.96 million. Current shares outstanding are 57.21 million.
The insiders hold 25.35% of the company’s shares while institutions hold 64.37%. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -93.22% down in year-to-date price movement.
